We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Researchers showed that deactivating interleukin 11 (IL11) with therapeutic antibodies reverses inflammation and scarring of the liver in patients suffering from an untreatable type of fatty liver disease / non-alcoholic steatohepatitis (NASH).